ArticleLeukemia2025

Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma.

Gayathri Ravi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.